this company, which is principally engaged in the manufacture of skincare products, cosmetics, food supplements and medicines used to treat skin diseases. The Company paid 20 million to the seller in
, medical device business is expected to be growth at an average rate of 8.5-10.0% per year. This growth will be supported by: (i) government policy, focused on promoting investment in the sector through the
which mainly due to commission income increased Baht 0.3 million and increased gain on exchange rate at Baht 0.1 million. For this year, as said, the gain on exchange rate at Baht 0.1 million while prior
or 26.61% from the same period last year, which can be described by business segment as follows: Industrial and OEM (B1) Revenue in this segment increased by Baht 20.84 million or 126.84% compared to
quarters of 2019, while on the downside we experience increased competitive pressure on our markets. This we plan to overcome with our efficient fixed cost base and continued focus on quality while widening
businesses will be the core platform for continuous growth in selective upstream & downstream integration over the next 5-10 years. On a proforma basis, this acquisition will add 25% to IVL’s 2018 core EBITDA
compared to the Q2 2018 of 127 million Baht. This was due to closure of two stores in the United States and in Thailand and also decrease in the sales of merchandise, gourmet food and beverage in the United
, Bangkok 10900, Thailand Fax : (662) 936-1669 ทะเบียนเลขท่ี 0107554000097 Registration No. 0107554000097 HYDROTEK PUBLIC COMPANY LIMITED บริษทั ไฮโดรเท็ค จ ำกดั (มหำชน) This Investment Disposal Transaction
, Bangkok 10900, Thailand Fax : (662) 936-1669 ทะเบียนเลขที่ 0107554000097 Registration No. 0107554000097 HYDROTEK PUBLIC COMPANY LIMITED บริษทั ไฮโดรเท็ค จ ำกดั (มหำชน) This Investment Disposal Transaction